Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.70 |
| ▸ | NOD1 | Q9Y239 | 12/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18869571 | 1.00 | GLP1R (0.70) | GLP1RNOD1 | |
| SCHEMBL23106986 | 0.98 | GLP1R (0.68) | GLP1RNOD1 | |
| SCHEMBL26076118 | 0.94 | GLP1R (0.77) | GLP1RNOD1 | |
| SCHEMBL15276351 | 0.93 | NOD1 (0.71) | GLP1RNOD1 | |
| SCHEMBL19034936 | 0.92 | GLP1R (0.61) | GLP1RNOD1 | |
| SCHEMBL19034927 | 0.92 | GLP1R (0.61) | GLP1RNOD1 | |
| SCHEMBL19034808 | 0.92 | GLP1R (0.61) | GLP1RNOD1 | |
| SCHEMBL19034989 | 0.92 | GLP1R (0.61) | GLP1RNOD1 | |
| SCHEMBL19034933 | 0.92 | GLP1R (0.61) | GLP1RNOD1 | |
| SCHEMBL18117511 | 0.92 | GLP1R (0.61) | GLP1RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562934-B2 | Modulation of complement activity | RA PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562934-B2 | Modulation of complement activity | C5, C3AR1, CFH | GLP1R 3416/4885NOD1 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.